Treating cancer patients with cell and gene therapy products, especially autologous products, is a process that must account for the needs and perspectives of patients, caregivers and treating physicians. Each of these stakeholders faces their own unique concerns and challenges, for example, with decision making, enrolling, scheduling, post-infusion management and long-term follow up.
Join this educational webinar to learn about the experiences of evaluating CAR T treatment options and the role of a multi-disciplinary team in enhancing a patient-centric approach. The discussion will examine critical considerations for nurses and physicians as well as the logistical hurdles that patients and caregivers face.
The speakers will also cover the additional challenges of ensuring trial continuity, pretreatment management and patient safety during the COVID-19 era as it relates to decentralized clinical trial solutions, such as telemedicine, home nursing and eConsent, which can help minimize risks in these complex trials and help support patients in their journey.
This webinar is part of a scientific series Covance is offering focused on trends, opportunities and challenges associated with current and future applications in Oncology. Learn more and register for upcoming webinars on topics such as adoptive T-cell therapies, biomarker technologies for the detection of rare cancer driver mutations and novel targeted therapies, and more.
Brian Hamilton, MD, PhD, Exec. Medical Director – Oncology, Covance by Labcorp
Dr. Hamilton is a medical doctor in Pediatrics, having been trained in Allergy/Immunology and Oncology, with clinical experience in hematopoietic stem cell transplantation. His PhD was in tumor and transplantation immunology. He has over 25 years of pharmaceutical industry experience including Immunology and/or Oncology positions at Astra (now AstraZeneca), Wyeth (now Pfizer), Merrimack, and Onyx (now Amgen). He has global experience in clinical development trials. Dr. Hamilton’s Oncology experience spans a wide variety of malignancies and therapeutics including cytotoxic chemotherapy, kinase inhibitors, monoclonal antibodies, immunotherapy, cellular immunothery, cancer vaccines and oncolytic viruses. Dr. Hamilton is located in Newton, MA.Message Presenter
Ira Braunschweig, MD, Clinical Program Director, Hematological Malignancies, Montefiore Medical Centre, NY
Dr. Ira Braunschweig is currently the Director of Stem Cell Transplantation and Clinical Program Director Hematologic Malignancies at the Montefiore/Einstein Center for Cancer Care.
Dr. Braunschweig graduated The New York University School of Medicine in 1992. After doing his residency in Internal Medicine at North Shore University Hospital Manhasset, N.Y., he trained in Hematology/Oncology and Stem Cell transplantation at the University of Texas MD Anderson Cancer Center in Houston, Texas and stayed on as a faculty member for three years.
For the last 18 years, Dr. Braunschweig has built the stem cell transplant/cellular therapy program at Montefiore into a robust program that performs over 115 transplants per year that includes autologous, allogeneic matched, matched unrelated donors, as well as haploidentical transplants.
Dr. Braunschweig has been at the forefront of the CAR-T cell revolution. He is a co-author on the pivotal Zuma-1 study, which established CAR-T therapy as a standard for relapsed and refractory malignant lymphoma (New England Journal of Medicine December 2017) as well as many other papers in the field of CAR-T.Message Presenter
Robyn Stacy-Humphries MD, Radiologist and Partner, Charlotte Radiology, and Lymphoma Cancer Survivor
Dr. Stacy-Humphries received her MD from UNC-Chapel Hill and competed a residency and fellowship at Georgetown University Hospital in Radiology and Body Imaging. Robyn was chief of radiology for 15 years at CMC-Union while also temporarily serving as a visiting clinical professor at UNC-CH.
Robyn was shockingly diagnosed with DLBCL in 2011 and failed standard chemo therapies of R-CHOP, R-ICE, Radiation and autologous SCT over 4 years. Due to her research and persistence, she was enrolled in the Novartis Juliet phase 2 trial of Kymriah in 2016 as one of 99 patients. Robyn has now been in remission for over 54 months and has spoken about her experience online with multiple medical journals, in person panel discussions about car-t for LLS/LRF and recently a Webinar for LRF discussing car-t.
Dr. Stacy-Humphries also administers a car-t support website with over 2500 members (patients and caregivers) from multiple countries which allows her insight into short and long term car-t benefits and risks. She is dedicated to helping other lymphoma patients who have failed standard therapies and now face car-t therapy while continuing to work full time as a radiologist, sub-specializing in mammography and oncologic imaging.Message Presenter
Debra Susarchick, Chief Product Officer and Head, Marketing, Trakcel
Debra started her career in the Pharmaceutical industry in 1996, when she joined Merck & Co., Inc., where she held positions on both Information Technology and Commercial teams. She then went to Celgene Corporation, where her focus was on Commercial innovation, enabling key transformational initiatives for the US Commercial Hematology/Oncology team. She then went to Kite Pharma where she directed the design, development and global launch of the Kite Konnect™ customer engagement platform, which supported the global launch of YESCARTA®, the first CAR-T for adult aggressive lymphoma. With Gilead, she holds two patents for the digitization of Chain of Identity and Chain of Custody. Building on her success at Kite, Debra then joined TrakCel at the end of 2019 and has successfully led TrakCel’s product transformation with the launch of OCELLOS by TrakCel, the first cellular orchestration platform available on the Salesforce App Exchange.Message Presenter
Who Should Attend?
Biopharmaceutical sponsors and researchers developing new therapeutics for solid tumors and hematologic malignancies
What You Will Learn
- The perspectives of patients, caregivers and treating physicians throughout the steps of treatment in a CAR T trial
- The role of a multi-disciplinary team throughout the patient journey
- The impact of COVID-19 on trials and how the use of technologies can address current challenges
- How to enhance a patient-centric approach to treatment
Covance by Labcorp
Covance by Labcorp is a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 26,000 people worldwide, we provide comprehensive drug development solutions and are on a mission to advance health and power clear, confident decisions.
Covance by Labcorp is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise.
Together with our clients, Covance by Labcorp supports the development of innovative, life-changing treatments. Visit us at www.covance.com.